Dear Doctor Letter (Rote-Hand-Brief) on Anemet 100 mg i.v.® (dolasetron): Renunciation of marketing authorisation
2011.02.18
Active substance: dolasetron
Due to the risk of arrhythmias in connection with the intravenous administration of dolasetron to adults for treatment of nausea and vomiting associated with cytostatic chemotherapy, the pharmaceutical manufacturer has renounced this marketing authorisation as a precautionary measure on its own responsibility. The medicinal product Anemet 100 mg i.v.® is recalled from pharmacies. The oral pharmaceutical forms remain unaffected by this measure.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN